A UC Irvine oncologist’s work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine.
The multicenter study is testing whether the drug crizotinib effectively slows, stops or reverses growth in advanced non-small cell lung cancer tumors by targeting a genetic mutation that causes uncontrolled tumor growth. Study participants all tested positive for a mutation in the anaplastic lymphoma kinase gene.
According to the findings, tumors disappeared or shrank in 57 percent of patients. Tumors ceased growing in another 33 percent. The response rate to the current standard of care for advanced non-small cell lung cancer is about 15 percent.
“For the majority of patients, the treatment right now is chemotherapy plus targeted therapy in those eligible,” said Dr. Ignatius Ou. “In the future, with the advance of personalized medicine, we hope to be able to identify specific genetic change in the lung cancer and treat patients with specific inhibitors that can improve survival rates and quality of life.”
The New England Journal of Medicine article includes data from 82 patients treated in Phase 1 of this study, sponsored by the pharmaceutical company Pfizer. The targeted genetic mutation is particularly prevalent among those who have never smoked. Study participants ranged in age from 25 to 78, with 76 percent of them nonsmokers.
Ou treated 15 patients in UCI’s Phase 1 trial, most from Los Angeles, Orange and San Diego counties. One person came from Arizona each month for treatment and assessment. Ou is currently enrolling patients in Phase 2 and 3 trials for crizotinib. Interested candidates should contact the UCI clinical trials office at 714-456-6241.
Each year, about 1.5 million new cases of lung cancer are diagnosed globally. Nearly 75 percent of people with non-small cell lung cancer are diagnosed at an advanced stage, for which the five-year survival rate is only 6 percent.
Recent cancer research emphasizes targeting, or personalizing, treatment through molecular analysis of a tumor and the use of a specific drug to inhibit genetic expression. Conventional chemotherapy bombards a tumor with multiple drugs.
According to the National Cancer Institute, because targeted cancer therapies are more selective for cancer cells, they may harm fewer normal cells, reduce side effects and improve quality of life.
About UC Irvine Medical Center: Orange County’s only university hospital, UC Irvine Medical Center offers acute- and general-care services at its new, 482,000-square-foot UC Irvine Douglas Hospital and is home to the county’s only Level I trauma center, American College of Surgeons-verified regional burn center and National Cancer Institute-designated comprehensive cancer center. U.S. News & World Report has included UC Irvine for 10 consecutive years on its list of America’s Best Hospitals, giving special recognition to its urology, gynecology, and ear, nose & throat programs.
About the University of California, Irvine: Founded in 1965, UCI is a top-ranked university dedicated to research, scholarship and community service. Led by Chancellor Michael Drake since 2005, UCI is among the most dynamic campuses in the University of California system, with nearly 28,000 undergraduate and graduate students, 1,100 faculty and 9,000 staff. Orange County’s largest employer, UCI contributes an annual economic impact of $3.9 billion. For more UCI news, visit www.today.uci.edu.
News Radio: UCI maintains on campus an ISDN line for conducting interviews with its faculty and experts. Use of this line is available for a fee to radio news programs/stations that wish to interview UCI faculty and experts. Use of the ISDN line is subject to availability and approval by the university.
John Murray | EurekAlert!
Finnish research group discovers a new immune system regulator
23.02.2018 | University of Turku
Minimising risks of transplants
22.02.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg
A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.
In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...
A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.
By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...
Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...
For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.
In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...
Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale
Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...
15.02.2018 | Event News
13.02.2018 | Event News
12.02.2018 | Event News
23.02.2018 | Physics and Astronomy
23.02.2018 | Health and Medicine
23.02.2018 | Physics and Astronomy